followed by XP-828L 5 g/d in group A and by XP-828L 10 g/d . The secondary objectives consisted in assessing the ef- . Anti-tu- mor necrosis factor agents ( etanercept, infliximab, adal- imumab) also have a proven efficacy.21 However, .